# Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

> **NCT05170334** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT05170334
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-15
- **Primary completion:** 2025-12-01
- **Final completion:** 2028-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170334, "Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05170334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*